320 related articles for article (PubMed ID: 22190683)
1. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
Kim W; Kim R; Park G; Park JW; Kim JE
J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
Kim W; Choi M; Kim JE
Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
[TBL] [Abstract][Full Text] [Related]
3. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
[TBL] [Abstract][Full Text] [Related]
4. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
[TBL] [Abstract][Full Text] [Related]
5. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
7. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
[TBL] [Abstract][Full Text] [Related]
8. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
Wakeman TP; Wang Q; Feng J; Wang XF
EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
[TBL] [Abstract][Full Text] [Related]
10. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
[TBL] [Abstract][Full Text] [Related]
11. The diverse functions of Dot1 and H3K79 methylation.
Nguyen AT; Zhang Y
Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
[TBL] [Abstract][Full Text] [Related]
12. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
13. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Vlaming H; McLean CM; Korthout T; Alemdehy MF; Hendriks S; Lancini C; Palit S; Klarenbeek S; Kwesi-Maliepaard EM; Molenaar TM; Hoekman L; Schmidlin TT; Altelaar AM; van Welsem T; Dannenberg JH; Jacobs H; van Leeuwen F
EMBO J; 2019 Jul; 38(14):e101564. PubMed ID: 31304633
[TBL] [Abstract][Full Text] [Related]
14. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
Wood K; Tellier M; Murphy S
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the DNA damage response and gene expression by the Dot1L histone methyltransferase and the 53Bp1 tumour suppressor.
FitzGerald J; Moureau S; Drogaris P; O'Connell E; Abshiru N; Verreault A; Thibault P; Grenon M; Lowndes NF
PLoS One; 2011 Feb; 6(2):e14714. PubMed ID: 21383990
[TBL] [Abstract][Full Text] [Related]
16. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
Wang F; Ngo J; Li Y; Liu H; Chen CH; Saifudeen Z; Sequeira-Lopez MLS; El-Dahr SS
Epigenetics; 2021 Nov; 16(11):1235-1250. PubMed ID: 33315499
[TBL] [Abstract][Full Text] [Related]
18. Rare de novo gain-of-function missense variants in DOT1L are associated with developmental delay and congenital anomalies.
Nil Z; Deshwar AR; Huang Y; Barish S; Zhang X; Choufani S; Le Quesne Stabej P; Hayes I; Yap P; Haldeman-Englert C; Wilson C; Prescott T; Tveten K; Vøllo A; Haynes D; Wheeler PG; Zon J; Cytrynbaum C; Jobling R; Blyth M; Banka S; Afenjar A; Mignot C; Robin-Renaldo F; Keren B; Kanca O; Mao X; Wegner DJ; Sisco K; Shinawi M; ; Wangler MF; Weksberg R; Yamamoto S; Costain G; Bellen HJ
Am J Hum Genet; 2023 Nov; 110(11):1919-1937. PubMed ID: 37827158
[TBL] [Abstract][Full Text] [Related]
19. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
Cao K; Ugarenko M; Ozark PA; Wang J; Marshall SA; Rendleman EJ; Liang K; Wang L; Zou L; Smith ER; Yue F; Shilatifard A
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27365-27373. PubMed ID: 33077595
[TBL] [Abstract][Full Text] [Related]
20. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]